Literature DB >> 12472570

A study on 289 consecutive Korean patients with acute leukaemias revealed fluorescence in situ hybridization detects the MLL translocation without cytogenetic evidence both initially and during follow-up.

Hee Jin Kim1, Han Ik Cho, Eui Chong Kim, Eun Kyong Ko, Cha Ja See, Seon Yang Park, Dong Soon Lee.   

Abstract

Translocations involving the MLL gene on the chromosome 11 (11q23) are frequently observed in acute leukaemia. The detection of this genetic change has a unique significance as a result of its implication of poor prognosis. To reveal the utility of fluorescence in situ hybridization (FISH) in detecting the MLL translocation, we analysed 289 consecutive Korean patients (children and adults) with acute leukaemias using both conventional cytogenetic analysis (CC) and FISH, placing an emphasis on the result discrepancies. Twenty-two of 289 patients (7.6%) had the 11q23/MLL translocation. In nine of 22 patients (41%), only FISH detected the translocation. In eight of these 22 patients, a total of 19 follow-up examinations were performed, of which FISH detected a significant level of leukaemic cells harbouring the MLL translocation in five patients (26%) without cytogenetic evidence. In addition to the MLL translocation, FISH detected submicroscopic amplification, partial deletion of the MLL gene and trisomy 11 in 12 patients without cytogenetic evidence. In summary, up to 41% of the MLL translocations at initial work-up and 26% during follow-up were detected by FISH without cytogenetic evidence. Thus, we recommend that MLL FISH should be performed in the diagnosis and monitoring of acute leukaemias in combination with CC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12472570     DOI: 10.1046/j.1365-2141.2002.03937.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  First description of the t(10;11)(q22;q23)/MLL-TET1 translocation in a T-cell lymphoblastic lymphoma, with subsequent lineage switch to acute myelomonocytic myeloid leukemia.

Authors:  Antoine Ittel; Eric Jeandidier; Catherine Helias; Nathalie Perrusson; Catherine Humbrecht; Bruno Lioure; Isabelle Mazurier; Caroline Mayeur-Rousse; Amandine Lavaux; Sylvie Thiebault; Felix Lerintiu; Carine Gervais; Laurent Mauvieux
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

2.  Genomic breakpoints and clinical features of MLL-TET1 rearrangement in acute leukemias.

Authors:  Sang-Guk Lee; Sun Young Cho; Min Jin Kim; Seung Hwan Oh; Eun Hae Cho; Sanggyu Lee; Eun Jung Baek; Jung Hye Choi; Stefan K Bohlander; Laurence Lode; Steven Richebourg; Hwi-Joong Yoon; Rolf Marschalek; Claus Meyer; Tae Sung Park
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

3.  Expression of CD133 in acute leukemia.

Authors:  Fetnat M Tolba; Mona E Foda; Howyda M Kamal; Deena A Elshabrawy
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

4.  Novel t(7;10)(p22;p24) along with NPM1 mutation in patient with relapsed acute myeloid leukemia.

Authors:  Santhi Sarojam; Sureshkumar Raveendran; Geetha Narayanan; Hariharan Sreedharan
Journal:  Ann Saudi Med       Date:  2013 Nov-Dec       Impact factor: 1.526

5.  Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.

Authors:  Jing Ye; Jie Zha; Yuanfei Shi; Yin Li; Delin Yuan; Qinwei Chen; Fusheng Lin; Zhihong Fang; Yong Yu; Yun Dai; Bing Xu
Journal:  Clin Epigenetics       Date:  2019-10-07       Impact factor: 6.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.